NVS Novartis AG
- 98.350
- +1.070+1.10%
- 97.010
- -1.340-1.36%
Novartis AG News
6-K: Financial Report Q1 2024
SC TO-T/A: Third party tender offer statement (Amendment)
SC 13D: Statement of acquisition of beneficial ownership by individuals-Novartis BidCo AG(11.56%),Novartis Pharma AG(11.56%), etc.
SC TO-T/A: Third party tender offer statement (Amendment)
SC TO-T/A: Third party tender offer statement (Amendment)
Novartis AG | SC TO-T/A: Third party tender offer statement (Amendment)
Novartis AG | SC TO-T: Third party tender offer statement
Novartis AG | S-8 POS: S-8 POS
Novartis AG | SC TO-C: Written communication relating to an issuer or third party tender offer
Novartis AG | SC TO-C: Written communication relating to an issuer or third party tender offer
Novartis AG | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(6.1%)
Novartis AG | 6-K: Report of foreign private issuer (related to financial reporting)
Novartis AG | IRANNOTICE: IRANNOTICE
Novartis AG | 6-K: Annual Report 2023 and Novartis in Society - Integrated Report 2023
Novartis AG | 20-F: Registration statement / Annual report / Transition report
Novartis AG | 6-K: Novartis Scemblix® Shows Superior Major Molecular Response (Mmr) Rates Vs. Standard-of-Care Tkis in Phase Iii Trial for Newly Diagnosed Patients with Chronic Myeloid Leukemia
Novartis AG | 6-K: Novartis Investigational Iptacopan Phase Iii Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3g)
Novartis AG | 6-K: Novartis Receives Fda Approval for Fabhalta® (Iptacopan)
Novartis AG | 6-K: Novartis Upgrades Mid-Term Sales Growth Guidance, Showcases Its Differentiated Innovative Medicines Strategy and Robust Pipeline at R&d Day
Novartis AG | 6-K: Report of Foreign Private Issuer
Analysis
Price Target
No Data
